Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04590170
Other study ID # APHP200812
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 30, 2020
Est. completion date April 30, 2024

Study information

Verified date November 2022
Source Assistance Publique - Hôpitaux de Paris
Contact Marie-Martine Lefevre-Colau, MD, PhD
Phone +33630480893
Email marie-martine.lefevre-colau@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to describe post-intensive care syndrome (PICS) of patients surviving to coronavirus disease 2019 (COVID19) and their rehabilitation and recovery process from hospital to home return


Description:

The novel coronavirus, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the COVID-19 emerged in December 2019 and was declared pandemic in March 2020. Although the majority of reported COVID-19 cases are mild, approximatively 5% of patients require a stay in intensive care unit, with mechanical ventilation. Post intensive care syndrome (PICS) consists of physical, cognitive and psychological dysfunctions. Little is known about the rate and clinical presentations of PCIS among patients surviving to COVID-19. The objective of this study is to describe the clinical manifestations of PCIS in COVID-19 patients, and their rehabilitation process until home return.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date April 30, 2024
Est. primary completion date October 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria - patients with covid19 infection : - COVID 19 infection (PCR or CT-scan) - ICU stay requiring mechanical ventilation - Age =18 years old Inclusion Criteria - control group : - Age = 18 years old - Able to walk without technical assistance, - Having no orthopedic or neurological disorder likely to disturb balance and walking - Have not had a severe form of Covid 19 disease in the last 12 months - Collection of non-opposition Exclusion Criteria: - Inability to give consent

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Post-intensive Care unit syndrome
Post-intensive Care unit syndrome after an intensive care unit stay for the COVID19
Other:
Spatiotemporal measurements of walking
Spatiotemporal measurements of walking in asymptomatic participants from the general population.

Locations

Country Name City State
France Department of Physical Medicine and Rehabilitation Issy-les-Moulineaux
France Department of Rehabilitation, Institute of Rheumatology Cochin Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change on cognitive Impairment: Vigilance (RASS) Used to measure the agitation or sedation level of a person. Range -5 to +4 - Patients group Between 10 days and 1 month after ICU's discharge
Primary Change on cognitive Impairment: Cooperation Yes/no - Patients group Between 10 days and 1 month after ICU's discharge
Primary Change on cognitive Impairment: Communication Yes/no - Patients group Between 10 days and 1 month after ICU's discharge
Primary Change on cognitive Impairment: Agitation Yes/no - Patients group Between 10 days and 1 month after ICU's discharge
Primary Change on cognitive Impairment: Delirium Yes/no - Patients group Between 10 days and 1 month after ICU's discharge
Primary Change on cognitive Impairment : Introduction of neuroleptic Yes/no - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on cognitive Impairment: temporo-spatial disorientation Yes/no - Patients group Between 10 days and 1 month after ICU's discharge
Primary Change on physical Impairment : dyspnea Yes/No - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment: Modified Borg scale dyspnea score. Verbal and numerical scale that asks you to rate the difficulty of your breathing Patients are asked to tick the boxes that reflect their dyspnea perception best range 0-10 lesser is better - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment : cough Yes/No - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment : respiratory rate Number of breaths/per minute. - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment : ventilation mode Tracheotomy/ ambient air / OXYGEN THERAPY Other - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment : Peripheral capillary oxygen saturation (SpO2) at rest measured by pulse oximetry, which provides an indirect measurement of arterial oxygenation (SaO2) based on the differential absorption of light by oxygenated and deoxygenated blood during pulsatile blood flow - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment : respiratory rate on activity respiratory rate breathing rate on activity - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment : Peripheral capillary oxygen saturation (SpO2) on activity measured by pulse oximetry, which provides an indirect measurement of arterial oxygenation (SaO2) based on the differential absorption of light by oxygenated and deoxygenated blood during pulsatile blood flow during activity - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment : orthostatic hypotension Yes/no drop in blood pressure that occurs when moving from a laying down (supine) position to a standing (upright) position. - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment : electrocardiogram at rest electrocardiogram at rest - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical impairment : numeric verbal scales of fatigue self-evaluation numeric verbal scales of fatigue - Patients group ranges (0-10) lesser is better Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment: numeric verbal scales of pain self-evaluation numeric verbal scales of pain ranges (0-10) lesser is better Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment : stiffness or pain involving joints Yes/No small joints (wrists, fingers, toes) and large joints (shoulders, elbows, hips, knees, ankles)
Patients group
Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment : stability of the trunk in siting Yes/no - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment : autonomy for bed-chair transfers Yes/no - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment autonomy for walking Yes/no - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment : sores Yes/no Localisation
Patients group
Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on Imagery cerebral date and result if applicable - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment neurologic exam motor or sensory deficits involving the upper and the lower limbs (yes/no) Anosmia Yes/no taste loss Yes/no
Patients group
Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment Medical Research Council (MRC-SS MRC Sum score) assess muscle strength from Grade 5 (normal) to Grade 0 (no visible contraction).
MRC-SS score was defined as the sum of MRC scores from six muscles in the upper and lower limbs on both sides so that the score ranged from 60 (normal) to 0 (quadriplegic).
Patients group
Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on physical Impairment five times sit to stand test The score is the amount of time (to the nearest decimal in seconds) it takes a patient to transfer from a seated to a standing position and back to sitting five times without use of arms, Equipment • Standard height chair (43-45 cm, 17-18 inches) with a backrest. If the patient cannot perform five stands to complete the test without use of arms, a score of 0 seconds should be documented.
Patients group
Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on cognitive Impairment The Montreal Cognitive Assessment (MoCA) Designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstruction skills, conceptual thinking, calculations, and orientation. Range 0 -30 higher is better
Patients group
Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Cognitive Impairment Frontal Assessment Battery (FAB) Total score is from a maximum of 18, higher scores indicating better performance.
Patients group
Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on psychological Impairment : sadness Yes/no - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on psychological Impairment : anxiety Yes/no - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on psychological Impairment: Insomnia Yes/no - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on psychological Impairment : Apathy Yes/no - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on psychological Impairment : sideration Yes/no - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on psychological Impairment : Despair Yes/no - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on psychological Impairment : Culpability Yes/no - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on psychological Impairment : Conduit addictive Yes/no - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on psychological Impairment : psychiatric or psychologic care Yes/no - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary assess type of psychiatric treatment Type - Patients group Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on psychological Impairment : Hospital Anxiety and Depression Scale (HADS) A 14-item self-report screening scale that was originally developed to indicate the possible presence of anxiety and depressive states It contains two 7-item scales: one for anxiety and one for depression both with a score range of 0-21.
Patients group
Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary Change on psychological Impairment : Posttraumatic Stress Disorder Checklist Scale (PCL-S) 20-item questionnaire, corresponding to the Manual of Mental Disorders (DSM-5) symptom criteria for PTSD.
Patients group
Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary assess psychological Impairment Introduction of antidepressant drugs Type
Patients group
Change between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Primary assess psychological Impairment Introduction of neuroleptic Type
Patients group
change between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Secondary asses demographics information Age, sex, formal education, marital status, occupation, place of living, socio-professional category
Patients group
Between 10 days and 1 month after ICU's discharge
Secondary assess comorbidities number of comorbidities
Patients group
Between 10 days and 1 month after ICU's discharge
Secondary assess past and current medications Precise
Patients group
Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Secondary assess related symptoms nature of COVID-19 duration of COVID-19-related symptoms nature Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay and/or CT-scan showing typical radiological findings
Patients group
Between 10 days and 1 month after ICU's discharge
Secondary assess characteristics of ongoing hospitalization number of characteristics of ongoing hospitalization (invasive ventilation, curare, others treatments )
Patients group
Between 10 days and 1 month after ICU's discharge
Secondary assess medical complications in intensive care Pneumopathy pulmonary embolism others
Patients group
Between 10 days and 1 month after ICU's discharge
Secondary Descriptive data of the rehabilitation care pathway after stay in intensive care until return home Number of days to discharge from hospital Service of rehabilitation care hospital at home (HAH) return at home
Patients group
Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Secondary Number of new medical qualifying events since last contact complications
Patients group
Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Secondary Social status professional activity unemployment retirement others
Patients group
Between 10 days and 1 month and 3 months and 6 months after ICU's discharge
Secondary Activities of Daily Living (ADL) scale Related to personal care (self-performance) looks at four of these tasks: transfer, bed mobility, toileting and eating. The resident's self- performance and the amount of staff support provided are evaluated for all of these tasks ranges from 0 (independent) to 4 (total dependence)
Patients group
3 months and 6 months after ICU's discharge
Secondary Quality of life Medical outcome study short form 12 items (MOS-SF-12 ) questionnaire Self-reported outcome measure assessing the impact of health on an individual's everyday life Patients fill out a 12-question survey which is then scored by a clinician or researcher.
Questionnaire consisting of 12 questions that measure 8 health domains to assess physical and mental health. Physical health-related domains include General Health (GH), Physical Functioning (PF), Role Physical (RP), and Body Pain (BP). Mental health-related scales include Vitality (VT), Social Functioning (SF), Role Emotional (RE), and Mental Health (MH).
Patients group
3 months and 6 months after ICU's discharge
Secondary Gait analysis 6-minute walk test (6MWT) Sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
Patients group
3 months and 6 months after ICU's discharge
Secondary Balance and Gait analysis Inertial Sensors to Assess Gait Quality
Patients group
3 months and 6 months after ICU's discharge
Secondary Spatio-temporal parameters of walking Comparison of spatio-temporal measures of walking in patients with severe Covid 19 infection to those of an age- and sex-matched sample of asymptomatic participants.
Both groups
Inclusion
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3